Geron share price today

(GERN)

Geron share price is $3.98 & -₹3.98 as on 12 Dec 2024, 2.30 'hrs' IST

$3.98

▲

-0.01

(-0.25%)

Market is closed - opens 8 PM, 12 Dec 2024

View live Geron share price in Dollar and Rupees. Guide to invest in Geron from India. Also see the sentimental analysis on Indian investors investing in Geron. Get details on the Indian mutual funds that are investing in Geron. Get Analyst recommendations and forecasts along with all the Geron's financials.

Geron share price movements

$3.93
$4.05
$3.98
1.26%
Downside
Day's Volatility :2.96%
Upside
1.73%
$1.64
$5.34
$3.98
58.79%
Downside
52 Weeks Volatility :69.29%
Upside
25.47%

Geron Returns

Period	Geron Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	-10.56%	-8.8%	0.0%
6 Months	-18.44%	-2.7%	0.0%
1 Year	90.43%	6.5%	0.0%
3 Years	199.25%	5.6%	-20.0%

Geron Key Statistics

in dollars & INR

Previous Close	$3.99
Open	$3.98
Today's High	$4.05
Today's Low	$3.93
Market Capitalization	$2.4B
Today's Volume	$5.1M
52 Week High	$5.34
52 Week Low	$1.64
Revenue TTM	$29.5M
EBITDA	$-207.5M
Earnings Per Share (EPS)	$-0.32
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-69.03%

How to invest in Geron from India?

It is very easy for Indian residents to invest directly in Geron from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Geron stock in both rupees (INR) and dollars (USD). Search for Geron or GERN on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Geron or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Geron shares which would translate to -0.003 fractional shares of Geron as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Geron

23.53%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Investment in Geron from India has grown in the last 30 days as on Dec 12, 2024. 23.53% more purchase transactions for Geron in the last 30 days versus the previous period.

-7%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for Geron on INDmoney from India has reduced in the last 30 days as on Dec 12, 2024. -7% less investors are searching Geron in the last 30 days versus the previous period.

Global Institutional Holdings in Geron

BlackRock Inc
7.70%
RTW INVESTMENTS, LLC
7.30%
Vanguard Group Inc
5.37%
RA Capital Management, LLC
5.34%
State Street Corp
4.79%
Adage Capital Partners Gp LLC
4.78%

Analyst Recommendation on Geron

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Geron(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Geron

What analysts predicted

Upside of 87.19%

Current:

$3.98

Target:

$7.45

Insights on Geron

Price Movement
In the last 1 year, GERN stock has moved up by 102.0%
Increasing Revenue
Revenue is up for the last 4 quarters, 23.0K → 28.27M (in $), with an average increase of 85.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -67.38M → -26.44M (in $), with an average increase of 154.8% per quarter

Geron Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.1M	↑ 0.09%
Net Income	$-27.0M	↓ 3.22%
Net Profit Margin	-2.5K%	↑ 86.79%

	FY19	Y/Y Change
Revenue	$460.0K	↓ 56.85%
Net Income	$-63.6M	↑ 135.23%
Net Profit Margin	-13.8K%	↓ 11281.0%

	FY20	Y/Y Change
Revenue	$253.0K	↓ 45.0%
Net Income	$-75.6M	↑ 18.98%
Net Profit Margin	-29.9K%	↓ 16069.95%

	FY21	Y/Y Change
Revenue	$1.4M	↑ 450.59%
Net Income	$-121.0M	↑ 59.97%
Net Profit Margin	-8.7K%	↑ 21202.54%

	FY22	Y/Y Change
Revenue	$596.0K	↓ 57.21%
Net Income	$-141.0M	↑ 16.6%
Net Profit Margin	-23.7K%	↓ 14980.42%

	FY23	Y/Y Change
Revenue	$237.0K	↓ 60.23%
Net Income	$-184.1M	↑ 30.56%
Net Profit Margin	-77.7K%	↓ 54027.46%

	Q2 FY23	Q/Q Change
Revenue	$29.0K	↑ 38.1%
Net Income	$-49.2M	↑ 29.29%
Net Profit Margin	-169.7K%	↑ 11556.48%

	Q3 FY23	Q/Q Change
Revenue	$164.0K	↑ 465.52%
Net Income	$-44.8M	↓ 8.98%
Net Profit Margin	-27.3K%	↑ 142428.16%

	Q4 FY23	Q/Q Change
Revenue	$23.0K	↓ 85.98%
Net Income	$-52.0M	↑ 16.0%
Net Profit Margin	-226.0K%	↓ 198653.79%

	Q1 FY24	Q/Q Change
Revenue	$304.0K	↑ 1221.74%
Net Income	$-55.4M	↑ 6.57%
Net Profit Margin	-18.2K%	↑ 207753.52%

	Q2 FY24	Q/Q Change
Revenue	$882.0K	↑ 190.13%
Net Income	$-67.4M	↑ 21.65%
Net Profit Margin	-7.6K%	↑ 10580.59%

	Q3 FY24	Q/Q Change
Revenue	$28.3M	↑ 3105.33%
Net Income	$-26.4M	↓ 60.75%
Net Profit Margin	-93.55%	↑ 7546.25%

	FY18	Y/Y Change
Total Assets	$185.3M	↑ 67.96%
Total Liabilities	$7.6M	↑ 15.88%

	FY19	Y/Y Change
Total Assets	$165.5M	↓ 10.67%
Total Liabilities	$30.4M	↑ 302.09%

	FY20	Y/Y Change
Total Assets	$270.7M	↑ 63.57%
Total Liabilities	$59.8M	↑ 96.89%

	FY21	Y/Y Change
Total Assets	$226.0M	↓ 16.51%
Total Liabilities	$99.6M	↑ 66.64%

	FY22	Y/Y Change
Total Assets	$190.6M	↓ 15.69%
Total Liabilities	$110.6M	↑ 11.0%

	FY23	Y/Y Change
Total Assets	$394.1M	↑ 106.78%
Total Liabilities	$146.1M	↑ 32.15%

	Q2 FY23	Q/Q Change
Total Assets	$415.3M	↓ 2.26%
Total Liabilities	$116.9M	↑ 18.26%

	Q3 FY23	Q/Q Change
Total Assets	$413.0M	↓ 0.55%
Total Liabilities	$122.4M	↑ 4.74%

	Q4 FY23	Q/Q Change
Total Assets	$394.1M	↓ 4.59%
Total Liabilities	$146.1M	↑ 19.38%

	Q1 FY24	Q/Q Change
Total Assets	$482.1M	↑ 22.33%
Total Liabilities	$137.2M	↓ 6.1%

	Q2 FY24	Q/Q Change
Total Assets	$449.4M	↓ 6.78%
Total Liabilities	$142.7M	↑ 4.01%

	Q3 FY24	Q/Q Change
Total Assets	$402.7M	↓ 10.39%
Total Liabilities	$110.4M	↓ 22.62%

	FY18	Y/Y Change
Operating Cash Flow	$-21.0M	↑ 2.2%
Investing Cash Flow	$-77.7M	↓ 438.35%
Financing Cash Flow	$93.0M	↑ 8267.96%

	FY19	Y/Y Change
Operating Cash Flow	$-43.8M	↑ 108.62%
Investing Cash Flow	$27.4M	↓ 135.26%
Financing Cash Flow	$19.5M	↓ 79.03%

	FY20	Y/Y Change
Operating Cash Flow	$-66.7M	↑ 52.07%
Investing Cash Flow	$-105.3M	↓ 484.38%
Financing Cash Flow	$168.3M	↑ 763.36%

	FY21	Y/Y Change
Operating Cash Flow	$-95.6M	↑ 43.37%
Investing Cash Flow	$71.9M	↓ 168.31%
Financing Cash Flow	$48.6M	↓ 71.16%

	FY22	Y/Y Change
Operating Cash Flow	$-127.4M	↑ 33.3%
Investing Cash Flow	$62.1M	↓ 13.73%
Financing Cash Flow	$87.3M	↑ 79.72%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-29.6M	↓ 36.16%
Investing Cash Flow	$-44.4M	↓ 75.13%
Financing Cash Flow	$18.3M	↓ 93.47%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-50.8M	↑ 71.75%
Investing Cash Flow	$-4.7M	↓ 89.39%
Financing Cash Flow	$29.4M	↑ 60.05%

Geron Technicals Summary

Sell

Neutral

Buy

Geron is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Geron Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Geron Corporation	0.25%	-18.44%	90.43%	199.25%	170.75%
Regeneron Pharmaceuticals, Inc.	-5.85%	-24.7%	-11.77%	17.09%	105.58%
Biontech Se	12.25%	24.31%	22.8%	-57.11%	240.97%
Alnylam Pharmaceuticals, Inc.	-5.5%	58.79%	40.79%	36.33%	111.58%
Vertex Pharmaceuticals Incorporated	-4.43%	-2.24%	15.61%	124.98%	113.34%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Geron Corporation	NA	NA	-2.38	-0.28	-0.69	-0.3	NA	0.49
Regeneron Pharmaceuticals, Inc.	19.27	19.27	1.17	45.03	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.24	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Geron Corporation	Buy	$2.4B	170.75%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$86.6B	105.58%	19.27	33.61%
Biontech Se	Buy	$28.0B	240.97%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$33.0B	111.58%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$122.1B	113.34%	32.84	-4.51%

Geron Dividend announcements

Geron Earnings
Geron’s price-to-earnings ratio stands at None
Read More

About Geron

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.

Organization	Geron
Employees	141
CEO	Dr. John A. Scarlett M.D.
Industry	Health Technology

Management People of Geron

Name	Title
Dr. John A. Scarlett M.D.	Chairman of the Board, President & CEO
Ms. Michelle J. Robertson	Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
Dr. Andrew J. Grethlein Ph.D.	Executive VP & COO
Mr. Scott Samuels	Executive VP, Chief Legal Officer & Secretary
Ms. Aron Feingold	Vice President of Investor Relations & Corporate Communications
Ms. Shannon Odam	Senior VP & Chief People Officer
Ms. Melissa A. Kelly Behrs	Executive VP of Business Operations & Chief Alliance Officer
Mr. Edward E. Koval	Executive VP & Chief Business Officer
Dr. Faye Feller M.D.	Executive VP & Chief Medical Officer
Mr. James Ziegler M.B.A.	Executive VP & Chief Commercial Officer

Important FAQs about investing in Geron from India :

What is Geron share price today?

Geron (GERN) share price today is $3.98.

Can Indians buy Geron shares?

Yes, Indians can invest in the Geron (GERN) from India.

With INDmoney, you can buy Geron at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Geron at zero transaction cost.

How can I buy Geron shares from India?

It is very easy to buy Geron from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Geron be purchased?

Yes, you can buy fractional shares of Geron with INDmoney app.

What are the documents required to start investing in Geron stocks?

To start investing in Geron, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.